About
Pharmacovigilance & Drug Safety
Introduction
About Pharmacovigilance & Drug Safety Case Discussions
?? Pharmacy Case Discussions
? Case-Based Learning
?? Pharmacy Courses
?? ICH E2A · WHO-UMC · CDSCO 2024
Pharmacovigilance & Drug Safety Case Discussions presents the real-world challenges of drug safety monitoring — from the unexpected serious adverse reaction requiring urgent ICSR filing to the emerging safety signal requiring systematic disproportionality analysis. Each case integrates WHO-UMC causality algorithms, regulatory reporting requirements, and ICH guidelines.
Each case in this series is structured around a real-world clinical presentation — combining history, examination, investigation results, and evidence-based management decisions. The case discussion format challenges participants to reason through differential diagnoses, justify investigation choices, and select guideline-directed treatments within the context of Pharmacovigilance & Drug Safety.
Cases are aligned to ICH E2A · WHO-UMC · CDSCO 2024 and cover: ADR Detection · Signal Detection · ICSR Reporting · Risk Management · Causality Assessment. The programme is designed for individual learners and multidisciplinary teams as a structured professional development tool.
Cases
Interactive Scenarios
Evidence
Guideline-Aligned
?? Case Discussion format. Each case begins with a clinical vignette and unfolds through guided questions — building diagnostic reasoning, investigation selection, and management decision-making anchored in ICH E2A · WHO-UMC · CDSCO 2024.
Master the Pharmacovigilance & Drug Safety Case Discussion.
Join the “Pharmacovigilance & Drug Safety Case Discussions” and build clinical reasoning through real-world case discussions aligned to ICH E2A · WHO-UMC · CDSCO 2024.
Who can enroll
Target Audience
Who can enroll
The “Pharmacovigilance & Drug Safety Case Discussions” is designed for healthcare professionals, students, and educators seeking to deepen their clinical reasoning through structured case discussions in pharmacovigilance & drug safety.
Whether you are a specialist clinician seeking CME credits, a resident building clinical competency, a student preparing for examinations, or an educator developing teaching materials — this programme provides evidence-based case discussions to meet your learning goals in pharmacovigilance & drug safety.
Designed for these professionals
??
01
Pharmacovigilance scientists and drug safety officers
??
02
Regulatory affairs pharmacists
??
03
Clinical pharmacists managing ADR reporting
??
04
Pharmacy students in pharmacovigilance rotations
?????
05
Medical affairs and drug safety personnel in pharma industry
???
06
Continuing professional development participants in drug safety
Your specialty. Your cases. Your practice.
Enrol in the “Pharmacovigilance & Drug Safety Case Discussions” and build expertise through evidence-based case discussions.
Programme Certification
Your certificate
Upon successful completion of this programme, you will receive a digital certificate recognising your achievement and the competencies you have acquired throughout the course.
Certificates for TerraLeap programmes are issued and signed by authorised TerraLeap representatives. For programmes delivered in collaboration with universities, institutions, or industry organisations, certificates are jointly issued and co-signed by authorised representatives of both TerraLeap and the respective partner.
Each certificate carries a unique Certificate ID and QR code to enable instant authenticity verification — making it easy to share with employers, licensing bodies, or professional networks as evidence of your learning.
Note on scope. TerraLeap certificates confirm successful completion of the respective programme and recognise your professional development and continuing education. They do not constitute a professional licence or regulatory authorisation unless explicitly stated in the programme description.
TERRALEAP
Certificate ID
TL-2026-AB7K3X9P
Official
Seal
Certificate of Completion
Successfully Completed
Awarded in recognition of academic achievement
This is to certify that
XXXXX
has successfully completed the prescribed course of study, demonstrating commitment, diligence, and proficiency in
Pharmacovigilance & Drug Safety
and is hereby awarded this certificate by TerraLeap, recognising the candidate's mastery of the syllabus and successful evaluation.